Jacobus Pharmaceutical Company Inc. Issues Voluntary Worldwide Recall of Ruzurgi® (amifampridine) 10 mg Tablets Due to Yeast, Mold, and Bacterial Contamination | FDA

Jacobus Pharmaceutical Company Inc. Issues Voluntary Worldwide Recall of Ruzurgi® (amifampridine) 10 mg Tablets Due to Yeast, Mold, and Bacterial Contamination | FDA: Plainsboro, New Jersey, Jacobus Pharmaceutical Company Inc. is voluntarily recalling 3 lots of Ruzurgi® (amifampridine) 10 mg tablets to the consumer level. The products have been found to be contaminated with yeast, mold, and aerobic bacteria based on laboratory test results. Oral products heavily

Comments

Post a Comment

Popular posts from this blog

Reduced public health measures contributed to deadly COVID-19 surge in the Americas, PAHO Director says - PAHO/WHO | Pan American Health Organization

Reduced public health measures contributed to deadly COVID-19 surge in the Americas, PAHO Director says - PAHO/WHO | Pan American Health Organization : Deaths rose to 202 people per hour in the Region, despite overall decline in cases. Washington D.C. February 16, 2022 (PAHO) – Complacency around mask wearing, travel, and indoor gatherings created a perfect opportunity for the new Omicron variant to spread rapidly throughout the region and increase deaths, alerted PAHO Director, Carissa F. Etienne, with many places remaining “just as they were before.”
Read more